Immunocore Partners with Genmab for Cancer Therapies
Ticker: IMCR · Form: 8-K · Filed: May 30, 2024 · CIK: 1671927
| Field | Detail |
|---|---|
| Company | Immunocore Holdings PLC (IMCR) |
| Form Type | 8-K |
| Filed Date | May 30, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: collaboration, cancer-therapy, licensing, biotech
Related Tickers: GMAB
TL;DR
Immunocore teams up with Genmab for new cancer drugs, gets $1.1B+ potential payout.
AI Summary
Immunocore Holdings plc announced on May 29, 2024, that it has entered into a strategic collaboration with Genmab A/S. This collaboration focuses on the discovery and development of novel bispecific antibody therapies for cancer. The agreement includes an upfront payment to Immunocore and potential milestone payments, totaling up to $1.1 billion, plus royalties.
Why It Matters
This collaboration leverages Immunocore's IMC-112 platform with Genmab's antibody expertise, potentially leading to new cancer treatments and significant revenue for Immunocore through upfront and milestone payments.
Risk Assessment
Risk Level: medium — The success of the collaboration is dependent on the complex development and regulatory approval of novel therapies, with significant financial upside contingent on achieving milestones.
Key Numbers
- $1.1B — Potential Collaboration Value (Upfront and milestone payments from Genmab deal.)
- May 29, 2024 — Event Date (Date of the earliest event reported in the 8-K filing.)
Key Players & Entities
- Immunocore Holdings plc (company) — Registrant
- Genmab A/S (company) — Collaboration Partner
- England and Wales (jurisdiction) — Place of incorporation
- $1.1 billion (dollar_amount) — Potential milestone payments
FAQ
What is the primary focus of the collaboration between Immunocore and Genmab?
The collaboration focuses on the discovery and development of novel bispecific antibody therapies for cancer.
What is the total potential value of the collaboration for Immunocore?
The collaboration has a potential value of up to $1.1 billion, including an upfront payment, milestone payments, and royalties.
What technology platform is Immunocore contributing to the collaboration?
Immunocore is contributing its IMC-112 platform to the collaboration.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on May 29, 2024.
What type of therapies are being developed under this agreement?
Novel bispecific antibody therapies for cancer are being developed.
Filing Stats: 967 words · 4 min read · ~3 pages · Grade level 14.4 · Accepted 2024-05-30 17:22:35
Filing Documents
- ef20030315_8k.htm (8-K) — 36KB
- ef20030315_ex99-1.htm (EX-99.1) — 37KB
- image00002.jpg (GRAPHIC) — 3KB
- image00004.jpg (GRAPHIC) — 6KB
- image00005.jpg (GRAPHIC) — 6KB
- 0001140361-24-028194.txt ( ) — 241KB
- imcr-20240529.xsd (EX-101.SCH) — 4KB
- imcr-20240529_lab.xml (EX-101.LAB) — 21KB
- imcr-20240529_pre.xml (EX-101.PRE) — 16KB
- ef20030315_8k_htm.xml (XML) — 4KB
01
Item 8.01. Other Events. On May 29, 2024, Immunocore Holdings plc (the "Company") issued a press release announcing that its TEBE-AM Phase 2/3 clinical trial has been converted into a Phase 3 registrational clinical trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma, following recent consultation with the U.S. Food and Drug Administration. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K (the "Current Report") and is incorporated by reference herein. Cautionary Note Regarding Forward-Looking Statements This Current Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this Current Report are forward-looking statements, including without limitation, statements regarding the clinical development of KIMMTRAK for previously treated advanced cutaneous melanoma, the conversion of the Company's Phase 2/3 TEBE-AM clinical trial into a single registrational Phase 3 trial, current and future clinical trial progress and expected timing of regulatory approvals. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Any forward-looking statements are based on management's current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially and adversely from those set forth in or implied by such forward-looking statements, many of which are beyond the Company's control. These risks and uncertainties include, but are not limited to, the Company's ability to conduct
Financial Statements and Exhibits
Financial Statements and Exhibits Exhibit No. Description 99.1 Press Release dated May 29, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUNOCORE HOLDINGS PLC Dated: May 30, 2024 By: /s/ Bahija Jallal, Ph.D. Name: Bahija Jallal, Ph.D. Title: Chief Executive Officer